<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>
  • Using technology in tumor genomics to develop precision cancer therapeutics

    Investor Relations

Investor Relations

Welcome to Trovagene Investor Relations

Corporate Profile

We are a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging our proprietary Precision Cancer Monitoring® (PCM) technology and experience in tumor genomics.  Our broad intellectual property and proprietary technology allow us to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting patient response to cancer therapies.  We offer our PCM technology at our CLIA/CAP-accredited laboratory and plan to continue to vertically integrate our PCM technology with the development of precision cancer therapeutics.  We believe our ctDNA PCM technology and expertise in liquid biopsy testing provides a unique advantage for the development of precision cancer therapeutics.

Company Overview - June 2017
Recent News
Jul 14, 2017

Trovagene, Inc. (NASDAQ:TROV), a precision medicine biotechnology company, today announced it has entered into a securities purchase agreement with certain accredited investors to purchase...

Jul 12, 2017

Trovagene, Inc. (NASDAQ: TROV), today announced that they have entered into an agreement with Novogene Co. Ltd., a leading global provider of genomic services and solutions with cutting edge...

Jul 10, 2017

Trovagene, Inc. (NASDAQ:TROV), a precision medicine biotechnology company, today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) indicating that the Company has...

More >

Stock Information
Contact Investor Relations

Direct     [USA +1] 858-952-7593
E-mail    ir@trovagene.com


June 15, 2017
12:00pm - 12:30pm PDT

Bill Welch, CEO of Trovagene, will be presenting at the Marcum 2017 MicroCap Conference on June 15, 2017 at 3:00 PM EDT at the Grand Hyatt Hotel in Julliard on the conference level. The...

June 7, 2017
11:30am - 12:00pm PDT

Trovagene CEO, Bill Welch, will be presenting at the 7th Annual LD Micro Invitational Conference June 7, 2017 at 11:30 AM PDT at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. The...

May 10, 2017
5:00pm - 6:00pm EDT

Trovagene's senior management team will host a conference call on Wednesday, MAy 10th, 2017, at 5:00 pm EDT (2:00 pm PDT) to discuss results and update investors on the Company's progress.

Wistia video thumbnail - Susann-Berz Patient Video- Home Page

Thanks for reporting a problem. We'll attach technical data about this session to help us figure out the issue. Which of these best describes the problem?

Any other details or context?